News
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bowel Disease. MAP 315, is a novel live biotherapeutic ...
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bowel Disease. MAP 315, is a novel live biotherapeutic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback